ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	US$0.000100	0.00%	62,521
30/09/26	US$0.000100	0.00%	500
29/09/26	US$0.000100	0.00%	250
28/09/26	US$0.000100	+9,900.00%	485
25/09/26	US$0.000001	-90.00%	100

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 20:47:07 02/10/2026 BST			5-day change	1st Jan Change
0.000100 ^USD	0.00%		+9,900.00%	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.64M 3.4M 3.1M 5.85M 394M 5.9M 41.16M 15.95M 202M 15.4M 15.06M 647M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.15M -1.07M -979K -1.85M -125M -1.86M -13M -5.04M -63.68M -4.87M -4.76M -204M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
11/04/23	Insider Buy: Obseva	MT
05/04/23	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
31/03/23	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/03/23	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/03/23	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/03/23	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
13/03/23	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/03/23	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/03/23	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/03/23	ObsEva SA Announces Executive Changes	CI
03/03/23	Top Premarket Gainers	MT

30/08/22	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/08/22	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/07/22	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/06/22	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/04/22	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Share Price

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news: ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Price Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
31/03/23	ObsEva Files Year End 2022 Financial Statements	GL
22/03/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/03/23	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/04/23	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/04/23	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/04/23	Bourse Zurich: ouverture en hausse avant le long week-end pascal
31/03/23	Obseva bleibt 2022 tief in den roten Zahlen
31/03/23	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		0.4
5 years	0		3.04
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
28/02/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23/02/23	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	0.00%	+9,900.00%	0.00%	-99.86%	11.72K
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.20%	+989.47%	+47.37%	+105.70%	39.05B
Weighted average by Cap.	+0.12%	-0.84%	+56.96%	+138.26%

	2021	2022
Net sales	-	19.64M 17.45M 16.28M 14.84M 27.99M 1.89B 28.25M 197M 76.36M 965M 73.73M 72.13M 3.1B
Net income	-58.38M -51.87M -48.41M -44.12M -83.22M -5.61B -83.99M -586M -227M -2.87B -219M -214M -9.21B	-29.88M -26.55M -24.78M -22.58M -42.59M -2.87B -42.99M -300M -116M -1.47B -112M -110M -4.71B
Net Debt	-28.08M -24.94M -23.28M -21.22M -40.02M -2.7B -40.39M -282M -109M -1.38B -105M -103M -4.43B	-5.4M -4.8M -4.48M -4.08M -7.69M -519M -7.77M -54.16M -20.99M -265M -20.26M -19.82M -851M